Gilead Buys Oxford Spin-out MiroBio

Gilead Sciences has agreed to acquire MiroBio, a privately held UK biotech focused on treating inflammatory diseases, for about $405 million in cash.

Spun out of Oxford University in 2019, MiroBio has a proprietary discovery platform and portfolio of immune inhibitory receptor agonists. The I-ReSToRE platform – Receptor Selection and Targeting to Reinstate immune Equilibrium – has potential to be used to develop best-in-class agonist antibodies targeting immune inhibitory receptors, a novel approach for the treatment of inflammatory diseases.

Chairman of MiroBio, Eliot Charles, commented: “MiroBio has a deep understanding of checkpoint receptor signaling and a proprietary approach to select and generate superior agonist antibodies. Combining this with Gilead’s drug development and therapeutic area expertise will allow us to fully explore the potential of checkpoint agonist antibodies for patients with autoimmune disease.”

MiroBio’s lead investigational antibody MB272 has entered Phase 1 clinical trials, and another – a PD-1 agonist – is reported to be in preclinical testing. Gilead anticipates advancing additional agonists from the I-ReSToRE platform over the next several years.

Author: Elaine Buridge, Freelance Journalist

© lichtmeister/shutterstock
© lichtmeister/shutterstock

Company

Gilead Sciences GmbH

Fraunhoferstr. 17
82152 Planegg

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.